✦ LIBER ✦

Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates

✍ Scribed by Rebecca Aft; Jose-Ricardo Perez; Noopur Raje; Vera Hirsh; Fred Saad

Book ID: 113555784
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 716 KB
Volume: 82
Category: Article
ISSN: 1040-8428
DOI: 10.1016/j.critrevonc.2011.05.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Delayed progression of bone metastases w

Delayed progression of bone metastases with bisphosphonate therapy: a randomised phase III trial with intravenous Aredia (pamidronate disodium) in breast cancer patients

✍ P.F. Conte; J. Latreille; L. Mauriac; L. Koliren; F. Calabresi; J.M. Ford 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 149 KB

A 99mTc-labeled gemcitabine bisphosphona

A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer

✍ Amal A. El-Mabhouh; Christo A. Angelov; Ron Cavell; John R. Mercer 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 202 KB

The role of Fas ligand and transforming

The role of Fas ligand and transforming growth factor β in tumor progression : Molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy

✍ Ryungsa Kim; Manabu Emi; Kazuaki Tanabe; Yoko Uchida; Tetsuya Toge 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB

## Abstract Despite the fact that expression of Fas ligand (FasL) in cytotoxic T lymphocytes (CTLs) and in natural killer (NK) cells plays an important role in Fas‐mediated tumor killing, During tumor progression FasL‐expressing tumor cells are involved in __counterattacking__ to kill tumor‐infiltr